CO6680604A2 - Forma cristalina de un compuesto 3-fenocimetilpirrolidina - Google Patents
Forma cristalina de un compuesto 3-fenocimetilpirrolidinaInfo
- Publication number
- CO6680604A2 CO6680604A2 CO13003305A CO13003305A CO6680604A2 CO 6680604 A2 CO6680604 A2 CO 6680604A2 CO 13003305 A CO13003305 A CO 13003305A CO 13003305 A CO13003305 A CO 13003305A CO 6680604 A2 CO6680604 A2 CO 6680604A2
- Authority
- CO
- Colombia
- Prior art keywords
- crystalline form
- crystalline
- phenoxymethylpyrrolidine
- compound
- salt
- Prior art date
Links
- -1 3-phenoxymethylpyrrolidine compound Chemical class 0.000 title 1
- 150000003839 salts Chemical class 0.000 abstract 3
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Urology & Nephrology (AREA)
- Nutrition Science (AREA)
- Psychology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrrole Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US36277310P | 2010-07-09 | 2010-07-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO6680604A2 true CO6680604A2 (es) | 2013-05-31 |
Family
ID=44510052
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO13003305A CO6680604A2 (es) | 2010-07-09 | 2013-01-09 | Forma cristalina de un compuesto 3-fenocimetilpirrolidina |
Country Status (20)
| Country | Link |
|---|---|
| US (4) | US8163794B2 (enExample) |
| EP (1) | EP2590941A1 (enExample) |
| JP (2) | JP5823512B2 (enExample) |
| KR (1) | KR20130041916A (enExample) |
| CN (1) | CN103038211B (enExample) |
| AR (1) | AR083512A1 (enExample) |
| AU (1) | AU2011276416B2 (enExample) |
| BR (1) | BR112013000602A2 (enExample) |
| CA (1) | CA2803090A1 (enExample) |
| CL (1) | CL2013000085A1 (enExample) |
| CO (1) | CO6680604A2 (enExample) |
| IL (1) | IL223584A0 (enExample) |
| MX (1) | MX2013000334A (enExample) |
| NZ (1) | NZ605490A (enExample) |
| PH (1) | PH12013500051A1 (enExample) |
| RU (1) | RU2013105479A (enExample) |
| SG (1) | SG186789A1 (enExample) |
| TW (1) | TW201206882A (enExample) |
| WO (1) | WO2012006205A1 (enExample) |
| ZA (1) | ZA201300154B (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2535669C2 (ru) * | 2009-07-13 | 2014-12-20 | Тереванс, Инк. | 3-феноксиметилпирролидиновые соединения |
| NZ605490A (en) * | 2010-07-09 | 2014-10-31 | Theravance Biopharma R & D Ip Llc | Crystalline form of a 3-phenoxymethylpyrrolidine compound |
| US12369722B2 (en) | 2018-05-23 | 2025-07-29 | L&P Property Management Company | Method of disassembling pocketed spring assembly with dimensionally stabilizing substrate |
| US11013340B2 (en) | 2018-05-23 | 2021-05-25 | L&P Property Management Company | Pocketed spring assembly having dimensionally stabilizing substrate |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020151712A1 (en) | 1999-09-14 | 2002-10-17 | Nan-Horng Lin | 3-pyrrolidinyloxy-3'-pyridyl ether compounds useful for controlling chemical synaptic transmission |
| DE60119047D1 (de) * | 2000-08-31 | 2006-06-01 | Pfizer | Phenoxyphenylheterozyklen als Serotonin-Wiederaufnahmehemmer |
| EP1725518A1 (en) * | 2004-03-05 | 2006-11-29 | Eli Lilly And Company | Pharmaceutical compounds |
| CA2661187A1 (en) * | 2006-08-23 | 2008-02-28 | Pfizer Products Inc. | Piperidine derivatives |
| US20100292288A1 (en) * | 2007-06-08 | 2010-11-18 | Arena Pharmaceuticals, Inc. | Crystalline forms of (r)-1-{2-[4`- (3-methoxy-propane-1- sulfonyl)-biphenyl-4-yl]-ethyl}-2-methyl-pyrrolidine, and compositions, and methods related thereto |
| JP5405571B2 (ja) * | 2008-07-24 | 2014-02-05 | セラヴァンス， インコーポレーテッド | ３−（フェノキシフェニルメチル）ピロリジン化合物 |
| WO2010120910A1 (en) * | 2009-04-15 | 2010-10-21 | Theravance, Inc. | 3-(phenoxypyrrolidin-3-yl-methyl)heteroaryl, 3-(phenylpyrrolidin-3-ylmethoxy)heteroaryl, and 3-(heteroarylpyrrolidin-3-ylmethoxy)heteroaryl compounds |
| RU2535669C2 (ru) * | 2009-07-13 | 2014-12-20 | Тереванс, Инк. | 3-феноксиметилпирролидиновые соединения |
| NZ605490A (en) * | 2010-07-09 | 2014-10-31 | Theravance Biopharma R & D Ip Llc | Crystalline form of a 3-phenoxymethylpyrrolidine compound |
-
2011
- 2011-06-30 NZ NZ605490A patent/NZ605490A/en not_active IP Right Cessation
- 2011-06-30 BR BR112013000602A patent/BR112013000602A2/pt not_active IP Right Cessation
- 2011-06-30 SG SG2012094348A patent/SG186789A1/en unknown
- 2011-06-30 KR KR1020137001583A patent/KR20130041916A/ko not_active Withdrawn
- 2011-06-30 AU AU2011276416A patent/AU2011276416B2/en not_active Ceased
- 2011-06-30 CN CN201180033815.4A patent/CN103038211B/zh not_active Expired - Fee Related
- 2011-06-30 JP JP2013518688A patent/JP5823512B2/ja not_active Expired - Fee Related
- 2011-06-30 PH PH1/2013/500051A patent/PH12013500051A1/en unknown
- 2011-06-30 WO PCT/US2011/042518 patent/WO2012006205A1/en not_active Ceased
- 2011-06-30 EP EP11738521.1A patent/EP2590941A1/en not_active Withdrawn
- 2011-06-30 US US13/173,204 patent/US8163794B2/en not_active Expired - Fee Related
- 2011-06-30 RU RU2013105479/04A patent/RU2013105479A/ru not_active Application Discontinuation
- 2011-06-30 CA CA2803090A patent/CA2803090A1/en not_active Abandoned
- 2011-06-30 MX MX2013000334A patent/MX2013000334A/es active IP Right Grant
- 2011-07-07 AR ARP110102429A patent/AR083512A1/es unknown
- 2011-07-08 TW TW100124302A patent/TW201206882A/zh unknown
-
2012
- 2012-03-20 US US13/424,561 patent/US8383669B2/en not_active Expired - Fee Related
- 2012-12-12 IL IL223584A patent/IL223584A0/en unknown
- 2012-12-19 US US13/720,385 patent/US8791151B2/en not_active Expired - Fee Related
-
2013
- 2013-01-07 ZA ZA2013/00154A patent/ZA201300154B/en unknown
- 2013-01-09 CO CO13003305A patent/CO6680604A2/es not_active Application Discontinuation
- 2013-01-09 CL CL2013000085A patent/CL2013000085A1/es unknown
-
2014
- 2014-06-24 US US14/313,422 patent/US9120746B2/en not_active Expired - Fee Related
-
2015
- 2015-03-26 JP JP2015063809A patent/JP2015120752A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| IL223584A0 (en) | 2013-03-05 |
| US8791151B2 (en) | 2014-07-29 |
| CN103038211B (zh) | 2015-04-15 |
| CN103038211A (zh) | 2013-04-10 |
| JP5823512B2 (ja) | 2015-11-25 |
| AU2011276416B2 (en) | 2015-04-02 |
| US20150080450A1 (en) | 2015-03-19 |
| KR20130041916A (ko) | 2013-04-25 |
| WO2012006205A1 (en) | 2012-01-12 |
| CL2013000085A1 (es) | 2013-03-15 |
| BR112013000602A2 (pt) | 2016-07-05 |
| US20120010265A1 (en) | 2012-01-12 |
| EP2590941A1 (en) | 2013-05-15 |
| US9120746B2 (en) | 2015-09-01 |
| US20120178790A1 (en) | 2012-07-12 |
| US20140018407A1 (en) | 2014-01-16 |
| PH12013500051A1 (en) | 2017-10-25 |
| JP2015120752A (ja) | 2015-07-02 |
| MX2013000334A (es) | 2013-02-26 |
| US8163794B2 (en) | 2012-04-24 |
| AU2011276416A1 (en) | 2013-02-14 |
| SG186789A1 (en) | 2013-02-28 |
| NZ605490A (en) | 2014-10-31 |
| US8383669B2 (en) | 2013-02-26 |
| ZA201300154B (en) | 2013-09-25 |
| CA2803090A1 (en) | 2012-01-12 |
| RU2013105479A (ru) | 2014-08-20 |
| AR083512A1 (es) | 2013-03-06 |
| TW201206882A (en) | 2012-02-16 |
| JP2013532170A (ja) | 2013-08-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX336497B (es) | Compuestos de tetrahidro-pirido-piridina y tetrahidro-pirido-pirim idina y su uso como moduladores de los receptores de c5a. | |
| UY32640A (es) | Aril-pirimidinas como inhibidoras de sintasa dfe aldosterona | |
| CR20130023A (es) | Pirazolo[1,5-a]pirimidinas para tratamiento antiviral | |
| ECSP11011391A (es) | Métodos y productos intermedios para preparar agentes farmacéuticos | |
| CR20150371A (es) | Inhibidores de prmt5 y sus usos | |
| GT201300174A (es) | Compuestos de indol o análogos de los mismos útiles para el tratamiento de la degeneración macular relacionada con la edad (dme) | |
| EA201391274A1 (ru) | Аминохинолины в качестве ингибиторов киназ | |
| EA201490567A1 (ru) | Новые бициклические производные дигидрохинолин-2-она | |
| EA201171488A1 (ru) | Lxr модуляторы | |
| BR112013016241A2 (pt) | composto, e, método para fabricar um composto | |
| UY32153A (es) | Inhibidores de piridomidinona de pi13ka(alfa) y mtor | |
| UA113750C2 (xx) | Склад (+)-2-$1-(3-етокси-4-метоксифеніл)-2-метансульфонілетил]-4-ацетиламіноізоіндолін-1,3-діону | |
| MY160392A (en) | Triptolide prodrugs | |
| CL2012002082A1 (es) | Proceso para la preparacion de lacosamida, por hidroximetilación; compuestos intermediarios. | |
| EP2672978A4 (en) | PERMEATION AMPLIFIER FOR TOPICAL FORMULATIONS | |
| EA201490756A1 (ru) | Разагилина цитрамид | |
| UY34142A (es) | Composiciones que contienen sal de colina para limpieza | |
| EA201490761A1 (ru) | R(+)-n-формилпропаргиламиноиндан | |
| CR11601A (es) | Pirimidil ciclopentanos hidroxilados en forma de inhibidores de akt proteina quinasa | |
| UY33348A (es) | Compuestos de furopiridina y usos de los mismos | |
| CO2019001644A2 (es) | Derivado de triazolopirazinona útil como un inhibidor de pde1 humana | |
| CO6680604A2 (es) | Forma cristalina de un compuesto 3-fenocimetilpirrolidina | |
| GT201400042A (es) | Compuesto de benzotiazolona | |
| GT201500124A (es) | Forma sòlida de un derivado de dihidro-pirido-oxazina | |
| EA201391419A1 (ru) | Пролекарства d-изоглутамил-[d/l]-триптофана |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Application refused |